Formulary guidance and transparency from P&T to point of care


Reality Check on Major Depressive Disorder

Market access for major depressive disorder treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 36% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: Nasal spray Spravato (esketamine) entered the market in spring 2019 as the first truly new product for major depressive disorder in years, but despite its potential to be a game-changer for those with treatmentresistant depression, most people with the condition will continue to be treated with tried-and-true generics
  • Key Findings: Coverage is heavily restricted for most brand-name products and processes under the pharmacy benefit for almost all products. Few MCOs will carve out antidepressants to the state Medicaid fee-for-service program

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.